<DOC>
	<DOCNO>NCT00151203</DOCNO>
	<brief_summary>PRIMARY STUDY OBJECTIVES - To evaluate efficacy combination clarithromycin ( Biaxin® ) , lenalidomide ( Revlimid™ ) , dexamethasone ( Decadron® ) induction therapy patient newly diagnose multiple myeloma ( MM ) . - To evaluate safety combination clarithromycin , lenalidomide , dexamethasone induction therapy patient newly diagnose MM . SECONDARY STUDY OBJECTIVES - To examine role clarithromycin pharmacokinetic property dexamethasone lenalidomide . - To examine angiogenesis profile untreated patient patient receive induction therapy .</brief_summary>
	<brief_title>Phase II Study Biaxin , Revlimid , Dexamethasone Untreated Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Subject must voluntarily sign understand write informed consent . Histologically confirm DurieSalomon stage II III MM ( see Appendix II ) . Stage I MM patient eligible display poor prognostic factor ( ß2M &gt; = 5.5 mg/L , plasma cell proliferation index &gt; = 5 % , albumin less 3.0 , unfavorable cytogenetics ) . Measurable disease define &gt; 1.0 g/dL serum monoclonal protein , &gt; 0.1 g/dL serum free light chain , &gt; 0.2 g/24 hr urinary Mprotein excretion , and/or measurable plasmacytoma ( ) . Age &gt; = 18 year time signing informed consent form . Karnofsky performance status &gt; = 70 % ( &gt; 60 % due bony involvement myeloma ( see Appendix V ) . No prior treatment le one full course firstline therapy . Patients may receive adjuvant antiresorptive therapy ( i.e. , pamidronate zoledronic acid ) routine care . If patient woman childbearing age , must negative serum urine pregnancy test within 7 day start study . Due unknown risk teratogenic side effect , subject ( woman men ) must agree use effective contraception throughout duration study least 1 month discontinuation study drug . Life expectancy &gt; 3 month Absolute neutrophil count ( ANC ) &gt; = 1000 cells/mm3 ( 1.0 x 109/L ) Platelets count &gt; = 75,000/mm3 ( 75 x 109/L ) Serum SGOT/AST &lt; 3.0 x upper limit normal ( ULN ) Serum SGPT/ALT &lt; 3.0 x upper limit normal ( ULN ) Serum creatinine &lt; 2.5 mg/dL ( 221 µmol/L ) Serum total bilirubin &lt; 2.0 mg/dL ( 34 µmol/L ) Patients nonsecretory MM ( measurable monoclonal protein , free light chain , and/or Mspike blood urine ) . Prior history malignancy ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless disease free ³ 5 year . NYHA Class III IV heart disease . History active angina , congestive heart disease , myocardial infarction within 6 month . Pregnant lactate woman ineligible . Known HIV positivity Active viral bacterial infection coexist medical problem would significantly increase risk treatment program . Known hypersensitivity dexamethasone , clarithromycin , lenalidomide , thalidomide . Prior therapy treatment MM History thromboembolic event condition currently require anticoagulation warfarin ( Coumadin ) . Patients whose therapy change heparin eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>newly diagnose multiple myeloma</keyword>
</DOC>